About Biomed Realty Trust (NYSE:BMR)
BioMed Realty Trust, Inc. operates as a real estate investment trust (REIT). The Company is the parent company and general partner of BioMed Realty, L.P. The Company owns, acquires, develops, redevelops, leases and manages laboratory and office space for the life science industry. The Company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are located in markets, which has centers for scientific research, including Boston, San Francisco, San Diego, Maryland, New York, New Jersey, Pennsylvania, North Carolina, Seattle, Cambridge (the United Kingdom) and research parks located near or adjacent to universities and their related medical systems. The Company owns interests in properties comprising approximately 17.5 million rentable square feet.
Industry, Sector and Symbol:
- Industry: Commercial REITs - NEC
- Sub-Industry: Office REITs
- Sector: Commercial REITs - NEC
- Symbol: NYSE:BMR
- CUSIP: 09063H10
- Web: www.biomedrealty.com
- Trailing EPS: $1.04
- Net Margins: 18.98%
- Return on Equity: 3.73%
- Return on Assets: 2.07%
Frequently Asked Questions for Biomed Realty Trust (NYSE:BMR)
What is Biomed Realty Trust's stock symbol?
Biomed Realty Trust trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMR."
How were Biomed Realty Trust's earnings last quarter?
Biomed Realty Trust Inc (NYSE:BMR) posted its quarterly earnings results on Tuesday, April, 28th. The real estate investment trust reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.04. The real estate investment trust earned $178.01 million during the quarter, compared to the consensus estimate of $167.08 million. Biomed Realty Trust had a net margin of 18.98% and a return on equity of 3.73%. Biomed Realty Trust's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.38 EPS. View Biomed Realty Trust's Earnings History.
Who are some of Biomed Realty Trust's key competitors?
Some companies that are related to Biomed Realty Trust include Digital Realty Trust (DLR), Realty Income Corporation (O), Vornado Realty Trust (VNO), Alexandria Real Estate Equities (ARE), Federal Realty Investment Trust (FRT), VEREIT (VER), Kilroy Realty Corporation (KRC), Douglas Emmett (DEI), Land Securities Group plc (LAND), Liberty Property Trust (LPT), British Land Company PLC (BLND), DuPont Fabros Technology (DFT), SEGRO plc (SGRO), EPR Properties (EPR), STORE Capital Corporation (STOR), Equity One (EQY), Hammerson plc (HMSO) and Cousins Properties Incorporated (CUZ).
Who are Biomed Realty Trust's key executives?
Biomed Realty Trust's management team includes the folowing people:
- Greg N. Lubushkin, Chief Financial Officer (Age 62)
- James R. Berens, President of Wexford Science & Technology (Age 61)
- Jonathan Paul Klassen, Executive Vice President, General Counsel, Secretary (Age 39)
- John P. Bonanno, Executive Vice President, Leasing & Development (Age 49)
- Karen A. Sztraicher, Executive Vice President - Asset Management (Age 51)
How do I buy Biomed Realty Trust stock?
Shares of Biomed Realty Trust can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Biomed Realty Trust?
Biomed Realty Trust's mailing address is 17190 Bernardo Center Dr, SAN DIEGO, CA 92128-7030, United States. The real estate investment trust can be reached via phone at +1-858-4859840.
MarketBeat Community Rating for Biomed Realty Trust (NYSE BMR)MarketBeat's community ratings are surveys of what our community members think about Biomed Realty Trust and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Biomed Realty Trust (NYSE:BMR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Biomed Realty Trust (NYSE:BMR)
Analysts' Ratings History for Biomed Realty Trust (NYSE:BMR)
(Data available from 11/18/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/22/2016||Canaccord Genuity||Reiterated Rating||Hold||N/A|
Earnings History and Estimates Chart for Biomed Realty Trust (NYSE:BMR)
Earnings History by Quarter for Biomed Realty Trust (NYSE BMR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2015||Q115||$0.37||$0.41||$167.08 million||$178.01 million||View||Listen|
|8/5/2014||Q214||$0.36||$0.40||$160.80 million||$171.16 million||View||Listen|
|8/7/2013||Q213||$0.39||$0.37||$143.47 million||$159.64 million||View||Listen|
|2/6/2013||Q412||$0.34||$0.36||$134.72 million||$138.80 million||View||Listen|
|11/1/2012||Q312||$0.33||$0.34||$130.32 million||$134.54 million||View||N/A|
Earnings Estimates for Biomed Realty Trust (NYSE:BMR)
No earnings estimates for this company have been tracked by MarketBeat.com
Current Dividend Information for Biomed Realty Trust (NYSE:BMR)
|Most Recent Dividend:||10/15/2015|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||100.00% (Trailing 12 Months of Earnings) |
|Track Record:||7 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Biomed Realty Trust (NYSE BMR)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Biomed Realty Trust (NYSE BMR)
Insider Trades by Quarter for Biomed Realty Trust (NYSE BMR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/17/2015||John P Bonanno||EVP||Sell||4,800||$21.01||$100,848.00|| |
|6/15/2015||James R Berens||Insider||Sell||2,000||$19.99||$39,980.00|| |
|6/15/2015||John P Bonanno||EVP||Sell||5,000||$19.85||$99,250.00|| |
|3/16/2015||Margaret Faye Wilson||Director||Buy||2,300||$21.76||$50,048.00|| |
|9/8/2014||Stephen A Willey||CAO||Sell||1,388||$22.50||$31,230.00|| |
|8/13/2014||Alan D Gold||CEO||Sell||26,615||$22.17||$590,054.55|| |
|8/13/2014||Matthew G Mcdevitt||VP||Sell||16,000||$22.01||$352,160.00|| |
|6/3/2014||Matthew G Mcdevitt||VP||Sell||7,000||$21.91||$153,370.00|| |
|5/14/2014||Alan Gold||CEO||Sell||25,000||$21.18||$529,500.00|| |
|5/12/2014||Stephen Willey||CAO||Sell||4,840||$21.00||$101,640.00|| |
|3/11/2014||Stephen Willey||CAO||Sell||7,931||$20.25||$160,602.75|| |
|2/11/2014||Matthew Mcdevitt||VP||Sell||60,000||$20.28||$1,216,800.00|| |
|11/23/2012||Matthew G Mcdevitt||VP||Sell||5,223||$19.05||$99,498.15|| |
Headline Trends for Biomed Realty Trust (NYSE:BMR)
Latest Headlines for Biomed Realty Trust (NYSE BMR)
Biomed Realty Trust (NYSE BMR) Chart for Saturday, November, 18, 2017